James A. Eastham MDChief, Urology Service, and Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
James A. Eastham, MD, is Chief of the Urology Service and Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology at Memorial Sloan-Kettering Cancer Center. His clinical expertise is in nerve-sparing radical prostatectomy for the treatment of prostate cancer, and salvage radical prostatectomy procedures in patients with prostate cancer in whom radiation therapy has failed.
His clinical research focuses on patient-reported outcomes for men treated with radical prostatectomy and clinical effectiveness of minimally-invasive techniques in the treatment of prostate cancer. He serves as a principal investigator on 6 clinical trials and a NIH-supported study investigating the comparative effectiveness of different radical prostatectomy approaches using large, population-based datasets and a prospective single-institution experience.
Dr. Eastham is a graduate of the University of Southern California. He completed his urology residency training at the University of Southern California Medical Center, then a fellowship in urologic oncology at Baylor University.
Recent Contributions to PracticeUpdate:
- Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate-Risk Prostate Cancer
- Identification of Patients at Risk for Biochemical Recurrence After Radical Prostatectomy
- Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
- Adjuvant Radiotherapy Following Radical Prostatectomy vs Radical Prostatectomy Alone in Men With Positive Margins or Extracapsular Extension
- Baseline PSA in Midlife and Aggressive Prostate Cancer in Black Men
- Erectile Function Recovery After Robotic-Assisted Radical Prostatectomy
- Prostate Cancer Screening: Balancing Benefits and Harms
- ERSPC: Screening and Prostate Cancer Mortality
- Establishing the Value of Multiparametric MRI in the Diagnosis of Prostate Cancer
- MRI-Fusion Biopsy for the Detection of Prostate Cancer